NR2B subunit selective NMDA receptor antagonists for treatment of depression, hearing and vision loss, and neurological damage

摘要

Use of NR2B subunit selective NMDA antagonists for treating certain disorders resulting from neurodegeneration and for treating depression is disclosed. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.